Prioritizing precision medicine for prostate cancer

Advancing precision medicine for prostate cancer through genomics.

Prostate cancer is the most common type of cancer in men and the second leading cause of cancer death in men in the United States. The recent surge of high-throughput sequencing of cancer genomes has supported an expanding molecular classification of prostate cancer. Translation of these basic science studies into clinically valuable biomarkers for diagnosis and prognosis and biomarkers that ar...

Precision Medicine for Personalized Cancer Therapy.

Precision medicine is defined as the tailoring of clinical strategies based on genomic, genetic, behavioral and environment background of individual patients. Statistics indicated that traditional clinical practices sometimes lead to poor health outcomes and a waste of medical resources. Medical waste due to unnecessary treatment or ineffective treatment amounted to 75 billion US dollars per ye...

Acquiring evidence for precision prostate cancer care

Cancer 2012; 118: 6055–6062. 16. Kim J, Jonasch E, Alexander A et al. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 2009; 15: 81–90. 17. Lin A, Piao HL, Zhuang L et al. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res 2014; 74: 1682–...

Translating genomics for precision cancer medicine.

The Human Genome Project not only provided the essential reference map for the human genome but also stimulated the development of technology and analytic tools to process massive quantities of genomic data. As a result of this project, new technologies for DNA sequencing have improved in efficiency and cost by more than a millionfold over the past decade, and these technologies can now be rout...

precision medicine for endocrinology